COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism
Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Fielmann Group accelerates international sales growth in Q2/2026 and increases pace of global expansion
Fielmann Group accelerates international sales growth in Q2/2026, with +6% growth driven by expansion strategies and AI technology. Preliminary HY1/2026 financials show €1.25bn in sales. Growth and increased staff capacity expected for HY2/2026 -
-
